Table 2B.
Characteristics of patients with SM‐AML.
| Pts | Diagnosis | Date (Year) | Age | KIT D816V | % Blasts in BM smear | % MC in BM smear | Morphology MC** | % MC infiltrate in tryptase stain* | KIT D816V MC*** | KIT D816V CD34+*** | MC CD2 positive in BM | MC CD25 positive in BM | Karyotype |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | AML | 1988 | 65 | ND | 72 | <1 | ND | ND | ND | ND | ND | ||
| #1 | SM‐MDS | 1995 | 72 | ND | 8 | 5 | a I | ND | ND | ND | 46 XX | ||
| #1 | SM‐AML | 1996 | 73 | pos | 60 | 2 | a I | 5 | Pos | Pos | ND | ND. | 46 XX |
| #2 | ISM | 1993 | 55 | ND. | <5 | <1 | a I | 30 | ND | ND | ND | ||
| #2 | SM‐AML | 1995 | 57 | ND | 42 | <1 | a I | 5 | ND | ND | 46 XX | ||
| #2 | SM‐AML | 1996 | 59 | neg | 55 | <1 | a I | 5 | ND | ND | 46 XX | ||
| #3 | ASM | 2001 | 59 | pos | 1 | 4 | a I | 70 | Neg | Pos | 46 XY | ||
| #3 | MCL | 2002 | 60 | pos | 2 | 42 | a II/MB | 99 | Neg | Pos | 46 XY | ||
| #3 | ASM‐RARS | 2005 | 62 | ND | 1 | 1 | a II | 20 | Neg | Pos | ND | ||
| #3 | ASM‐AML | 2005 | 63 | pos | 25 | 1 | a II | 60 | Pos | Neg | Neg | Pos | ND |
| #4 | ASM‐CMML | 2000 | 52 | pos | 0 | 2 | a I | 50 | Neg | Pos | 46 XX | ||
| #4 | ASM‐AML | 2002 | 54 | pos | 81 | 1 | a I | 10 | Pos | Neg | Neg | ND | 46 XX |
| #4 | ASM‐CMML | 2002 | 54 | pos | 10 | 1 | a I | 20 | ND | ND. | 46 XY | ||
| #5 | ISM‐AML | 2002 | 57 | pos | 8 | <1 | a I | 5 | ND | ND | 47 XY,del(20),+22 | ||
| #6 | ASM‐CMML | 2001 | 53 | pos | ND | ND | ND | 70 | ND | ND | 46 XY | ||
| #6 | ASM‐AML | 2003 | 55 | pos | 53 | 1 | a I | <5 | Pos | Pos | ND | ND. | 46 XY,der(7),t(7;15) |
| #7 | ASM‐CMML | 2003 | 71 | pos | 1 | 2 | a I | 10 | ND | Pos | 46 XY | ||
| #7 | ASM‐AML | 2004 | 72 | pos | 53 | 1 | a I | <5 | ND | ND | 46 XY | ||
| #8 | ISM‐CMML | 2002 | 73 | ND | 5 | <1 | ND | <1 | ND. | ND. | ND | ||
| #8 | ISM‐AML | 2003 | 74 | pos | 30 | 1 | a I | 3 | Neg | Pos | ND |
SM indicates systemic mastocytosis; AML, acute myeloid leukemia; Pts, patients; BM, bone marrow; MC, mast cell; MDS, myelodysplastic syndrome; ISM, indolent systemic mastocytosis; ASM, aggressive systemic mastocytosis; MCL, mast cell leukemia; RARS, refractory anemia with ringed sideroblasts; CMML, chronic myelomonocytic leukemia; ND, not determined; pos, positive; neg, negative. Mast cell morphology (Sperr et al., 2001a,b): a I, atypical mast cell type I: spindle‐shaped hypogranulated mast cells with oval nucleus; a II, atypical mast cell type II with bilobed nuclei; and MB, metachromatic blasts. * Immunohistochemical analysis. **Predominant type of MC in bone marrow smears. ***KIT mutation analysis in microdissected MC and CD34+ cells.